Background: The demand for a milder, yet effective dilation drop prompted Allergan to introduce Paremyd™ to the eye care community in 1993. This study sought to form clinical comparisons between Paremyd™ and the standard drug regimen for dilation of 1% tropicamide/2.5% phenylephrine.
Methods: 23 subjects who ranged from 23-29 years of age were dilated with 1 drop each of 1% tropicamide and 2.5% phenylephrine in the right eye and 1 drop of Paremyd™ in the left eye. Pupil diameter and accommodative amplitude (using the push up method) was evaluated at 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180 minute intervals while intraocular pressures were attained at 0, 30, 60, 120 and 180 minute intervals.
Results: Analysis revealed that Paremyd™ had a slightly less mydriatic and cycloplegic effect than the standard drug regimen. There was also a difference in efficacy when segregating participants due to irides' color with both dilation methods having a greater mydriatic effect on non-brown eyed vs. brown eyed subjects. The reverse was true when cycloplegic effect was analyzed.
Conclusions: It is difficult to assess which regimen should be the drug or drugs of choice with regard to pupil dilation. Paremyd™ proves to be an effective, milder mydriatic agent. Although in brown eyed individuals, one drop of Paremyd™ may fall slightly short of the desired 7 mm dilated pupil.
Files are restricted to Pacific University. Sign in to view.